Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effectiveness and Prognostic Factors of Everolimus in Patients with Pancreatic Neuroendocrine Neoplasms

Published:2023-01-15 Issue:2 Volume:62 Page:159-167
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Kurita Yusuke¹,Kobayashi Noritoshi²,Hara Kazuo³,Mizuno Nobumasa³,Kuwahara Takamichi³,Okuno Nozomi³,Haba Shin³,Tokuhisa Motohiko²,Hasegawa Sho¹,Sato Takamitsu¹,Hosono Kunihiro¹,Kato Shingo¹,Kessoku Takaomi¹,Endo Itaru⁴,Shimizu Yasuhiro⁵,Kubota Kensuke¹,Nakajima Atsushi¹,Ichikawa Yasushi²,Niwa Yasumasa⁶

Affiliation:

1. Department of Gastroenterology and Hepatology, Yokohama City University, Japan

2. Department of Oncology, Yokohama City University, Japan

3. Department of Gastroenterology, Aichi Cancer Center, Japan

4. Department of Gastroenterological Surgery, Yokohama City University, Japan

5. Department of Gastroenterological Surgery, Aichi Cancer Center, Japan

6. Department of Endoscopy, Aichi Cancer Center, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/62/2/62_9416-22/_pdf

Reference30 articles.

1. 1. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26: 3063-3072, 2008.

2. 2. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514-523, 2011.

3. 3. Lee L, Igarashi H, Fujimori N, et al. Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study. Jpn J Clin Oncol 45: 1131-1138, 2015.

4. 4. Panzuto F, Boninsegna L, Fazio N, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 29: 2372-2377, 2011.

5. 5. Kamp K, Gumz B, Feelders RA, et al. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after¹⁷⁷Lu-octreotate. Endocr Relat Cancer 20: 825-831, 2013.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis;Journal of Gastrointestinal Oncology;2024-04

2. Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope;World Journal of Gastroenterology;2024-03-28

3. Mixed squamous – neuroendocrine carcinoma of the gallbladder: A case report of a rare pathological entity;Cancer Research, Statistics, and Treatment;2024-01

4. Predictive Factors of Response to Streptozotocin in Neuroendocrine Pancreatic Neoplasms;Journal of Clinical Medicine;2023-12-07

5. Predicting Liver Metastasis in Pancreatic Neuroendocrine Tumor After Surgery: A Population-Based Study;2023-10-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3